Peter Attia MD406 ‒ Migraine, cluster headache, and tension headache: symptoms, causes, prevention, and treatment
CHAPTERS
- 0:01 – 6:14
Headache medicine’s training gap and Brian’s path into the field
Peter introduces Brian Grosberg and explores how headache medicine is under-taught in medical training despite headaches being extremely common. Brian explains how a single, debilitating patient early in residency—and a future mentor—pulled him into specializing in headache care.
- •Headache as a ubiquitous neurologic symptom, yet minimal coverage in med school/residency
- •Brian’s early residency case: prolonged, disabling migraine and the turning point it created
- •Mentorship and self-driven “extra” training before formal fellowship
- •Why headaches are uniquely challenging: diagnosis relies heavily on history, not imaging
- 6:14 – 10:26
Why history matters: headaches rarely have biomarkers or definitive imaging findings
The conversation frames headache as a symptom with an unusually broad differential diagnosis. Brian explains how clinicians distinguish causes primarily through careful history, separating primary headache syndromes from secondary headaches caused by another condition.
- •No single CT/MRI finding typically ‘proves’ a primary headache diagnosis
- •Headache differential is vast (hundreds of entities)
- •Primary vs. secondary headaches: the International Classification of Headache Disorders framework
- •Patient fears (tumor/aneurysm) vs. reality: most headaches are not dangerous but still disabling
- 10:26 – 13:40
Primary headaches: tension-type vs. migraine—how to tell them apart
Brian lays out practical diagnostic criteria for tension-type headache and migraine, emphasizing real-world nuances (e.g., migraine can be bilateral). He also explains how symptom framing can uncover light/sound sensitivity patients don’t initially report.
- •Tension-type headache: bilateral, mild–moderate, non-throbbing, no nausea; light or sound sensitivity but not both
- •Migraine criteria: duration 4–72 hours, features such as throbbing, activity avoidance, nausea and/or light/sound sensitivity
- •Migraine can be bilateral in a substantial minority—common misconception
- •Reframing questions improves symptom detection (e.g., preference for dark/quiet rooms)
- 13:40 – 15:31
Migraine attack profiles and allodynia: details that change treatment timing
The discussion shifts from diagnosis to how migraine ‘attack profiles’ vary within the same person, affecting treatment choices. Brian introduces allodynia—pain from normally non-painful stimuli—and why delayed treatment can reduce triptan effectiveness.
- •Migraine attacks differ: gradual build vs. waking from sleep, timing, nausea/vomiting, disability level
- •Allodynia definition and examples (hair brushing, ponytail, hats, glasses)
- •Allodynia’s clinical importance: later triptan use may be less effective
- •Treatment strategy depends on onset speed, symptoms, and functional impact
- 15:31 – 18:00
Migraine phases: prodrome, aura, headache phase, and postdrome
Brian explains migraine as a multi-phase neurologic disorder rather than ‘just a headache.’ He outlines the premonitory (prodromal) symptoms, what aura is and how it unfolds, and the lingering postdrome that can impair function even after pain resolves.
- •Premonitory symptoms (yawning, cravings, irritability, neck stiffness) often hours before onset
- •Aura: reversible neurologic symptoms; most migraineurs do not experience aura
- •Cortical spreading depolarization and typical 5–60 minute gradual evolution
- •Postdrome ‘hangover’ and its contribution to overall migraine burden
- 18:00 – 20:30
Aura vs. stroke/TIA: patterns that help distinguish emergencies from migraine
Peter probes how clinicians differentiate migraine aura from cerebrovascular events. Brian highlights the importance of symptom evolution, recurrence, and the presence of positive vs. negative neurologic phenomena.
- •Stroke/TIA symptoms are often maximal at onset; aura typically spreads gradually
- •Stereotyped, recurrent episodes support aura more than one-off events
- •Positive + negative visual phenomena suggest aura; purely negative visual loss suggests TIA/stroke
- •History of migraine strongly informs probability—but mimics must be excluded
- 20:30 – 25:45
Migraine’s burden: prevalence, disability, women’s disproportionate impact, and specialist shortage
The episode quantifies migraine’s enormous public-health footprint and how it reduces productivity through both absenteeism and presenteeism. Brian emphasizes the disproportionate impact on women and the limited number of fellowship-trained headache specialists.
- •Prevalence: ~12% overall; ~1 billion worldwide; ~45 million in the U.S.
- •Economic burden: major costs from presenteeism (impaired work performance)
- •Sex disparity: ~18% of women affected; ~3:1 female-to-male ratio
- •Chronic migraine definition (≥15 headache days/month) affects ~1–2% of population
- •Workforce mismatch: only ~50 new headache specialists/year (approx.)
- 25:45 – 35:02
Hormones and genetics: menstrual migraine, perimenopause, and estrogen-withdrawal dynamics
Brian breaks down migraine’s multifactorial roots, highlighting genetic susceptibility and the strong influence of hormonal transitions. The discussion dives into menstrual migraine subtypes and evidence suggesting rapid estrogen decline (late luteal phase) as a key driver.
- •Migraine risk increases with family history; polygenic susceptibility and hyperexcitable nervous system
- •Hormonal milestones: puberty, menses, pregnancy/lactation, perimenopause/menopause
- •Pure menstrual migraine vs. menstrual-related migraine and their frequencies
- •Evidence favors rapid late-luteal estrogen decline as a distinguishing feature in migraineurs
- •Perimenopause can worsen migraine; menopause improves migraine in many but not all
- 35:02 – 45:19
Triggers vs. causes—and why headache diaries often outperform ‘high-tech’ tracking
The conversation clarifies that triggers don’t ‘cause’ migraine in non-susceptible people but can precipitate attacks in those predisposed. Brian and Peter emphasize diaries as a core tool for pattern recognition, menstrual correlation, and building preemptive strategies.
- •Triggers are precipitants on a biologic susceptibility background; some patients report no triggers
- •Common precipitants: weather changes, stress letdown, food/alcohol, schedule shifts
- •Headache diary value: reveals multi-trigger stacks (sleep-in + delayed caffeine + stress release)
- •Menstrual pattern confirmation typically requires tracking across multiple cycles
- •Diaries enable preemptive treatment planning (e.g., anticipated perimenstrual attacks)
- 45:19 – 47:10
Tension-type headache: prevalence, features, and when simple OTC treatment is enough
Brian returns to tension-type headache to clarify misconceptions about ‘tension’ and stress. He outlines its typical symptom profile, contributing factors (muscle tenderness and overlapping nerve pathways), and when OTC analgesics can be appropriate.
- •Often evenly distributed between sexes and very common across the population
- •Typical pattern: non-throbbing, mild–moderate, bilateral head/neck involvement
- •May involve pericranial muscle tenderness; overlaps in head/neck sensory pathways
- •OTC acetaminophen/NSAIDs can help when diagnosis is clear
- •Chronic tension-type headache exists (≥15 days/month) and may warrant prevention in select cases
- 47:10 – 56:38
Cluster headache: hallmark symptoms, circadian/seasonal patterns, and frequent misdiagnosis
Brian describes cluster headache as rare but among the most painful known disorders, often with visible autonomic signs. He explains its rapid onset, side-locked pain, agitation/restlessness, seasonal/circadian periodicity, and why it’s often mistaken for sinus or dental problems.
- •Severe unilateral peri-orbital pain with rapid peak (5–15 minutes) and short attacks (15 min–3 hours)
- •Prominent autonomic signs (tearing, red eye, nasal congestion) and restlessness
- •Episodic vs. chronic cluster; up to multiple attacks/day during cluster periods
- •Circannual/circadian patterns implicate hypothalamus/pineal involvement; clock changes can provoke flares
- •Misdiagnosis as sinusitis/allergies/dental disease can lead to unnecessary procedures
- 56:38 – 1:11:53
Lifestyle and risk-factor modification: preventing chronification and reducing attack burden
The episode shifts to prevention through modifiable factors, especially for migraine progression to higher-frequency states. Brian highlights key risks like sleep disruption, mood comorbidity, medication overuse, obesity, and untreated nausea—then explains why regularity is protective in a hypersensitive nervous system.
- •Migraine chronification risks: frequent baseline attacks, sleep disturbance, stress, mood disorders
- •Medication overuse risk (even ~2+ days/week regularly) can worsen headache frequency
- •Obesity increases chronification risk; weight loss (surgical/non-surgical) can improve migraine
- •Regularity matters: consistent sleep, meals, hydration, exercise; stress-reduction tools (CBT, biofeedback, meditation)
- •Cluster-specific lifestyle considerations: alcohol avoidance during cycles, sleep apnea/hypoxia considerations
- 1:11:53 – 1:16:47
Preventive pharmacology: what ‘prevention’ can realistically achieve and who needs it
Brian defines the goals of preventive therapy (reduce frequency/intensity/duration, improve acute response, reduce interictal burden) and when it’s indicated. He notes a major care gap: many eligible patients never receive preventive therapy.
- •Prevention aims for reduction and better function—not a ‘cure’
- •Indications: frequent or disabling attacks, contraindicated/ineffective acute options, certain subtypes
- •Population-level estimate: ~40% of migraine patients may qualify, but far fewer receive prevention
- •Cluster headache prevention is commonly necessary due to attack frequency/severity
- •Expectation-setting: benefits often take weeks to months (‘not Amazon Prime’)
- 1:16:47 – 1:24:07
Preventive drug classes: beta blockers, antidepressants, anti-seizure meds, calcium channel blockers, and Botox
Brian reviews commonly used preventive medication classes, stressing individualized selection based on comorbidities and side effects. He explains Botox’s evidence base for chronic migraine and verapamil’s central role in cluster headache prevention, sometimes requiring very high doses with cardiac monitoring.
- •Beta blockers (e.g., propranolol/timolol): effective for some; caution in asthma/exercise intolerance
- •Tricyclics (amitriptyline/nortriptyline): low-dose use for migraine; may help insomnia; stigma addressed
- •Anti-seizure meds (topiramate/valproate): effects on channels, glutamate/GABA; pregnancy considerations
- •Verapamil: cornerstone for cluster prevention; may require high dosing + EKG monitoring
- •Botox (PREEMPT protocol): indicated for chronic migraine; injections across head/neck/shoulders; insurance step-therapy hurdles
- 1:24:07 – 1:29:12
Migraine pathophysiology deep dive: trigeminal system, neurovascular signaling, and CGRP cascade
Brian provides a mechanistic explanation of migraine as a neurovascular disorder involving trigeminal pathways, sensitization, and neurogenic inflammation. He traces how CGRP emerged as a therapeutic target through physiologic studies and triptan-era observations.
- •Pain-sensitive structures: dura and intracranial blood vessels; brain parenchyma itself is insensate
- •Trigeminal nerve pathways and convergence with upper cervical roots explain neck pain
- •Peripheral vs. central sensitization; allodynia as a clinical marker of central sensitization
- •Neuropeptide/inflammatory cascade (CGRP, substance P, nitric oxide, mast cells, histamine)
- •CGRP elevations during attacks and normalization with sumatriptan helped validate CGRP targeting
- 1:29:12 – 1:43:36
CGRP-targeted therapies: monoclonal antibodies and gepants—impact, response rates, and trial-and-error reality
Building on the mechanism, Brian explains CGRP monoclonal antibodies (monthly self-injection or quarterly infusion) and oral/nasal gepants (acute and sometimes preventive). He emphasizes real-world response variability, delayed responders, and that nonresponse to one agent doesn’t rule out the class.
- •mAbs: long half-life (~28 days), monthly injections; one option is quarterly infusion
- •Clinical impact is substantial, but not universal; ~60% benefit with varying degrees of response
- •Some respond in 1 month; others need 3–4 months
- •Gepants: small-molecule CGRP antagonists (acute; some preventive/dual-indication)
- •Cost/access barriers: insurance variability, formularies, and broader societal cost tradeoffs
- 1:43:36 – 1:52:12
Acute (rescue) treatment: NSAIDs, triptans/ergots, avoiding opioids, and choosing the right formulation
Brian outlines acute treatment options, separating nonspecific analgesics from migraine-specific therapies. He explains why opioids and barbiturate combinations can worsen long-term outcomes, and how triptan choice depends on onset speed, nausea/gastric stasis, and needed time-to-relief.
- •Nonspecific options: acetaminophen, NSAIDs; role depends on diagnosis and attack severity
- •Opioids and Fioricet/Fiorinal: high medication-overuse risk; generally avoided except last-line
- •Triptans: 5-HT1B/1D agonists; seven options with different kinetics/formulations
- •Route matters: injection often fastest (critical for cluster; ~minutes to relief), nasal/oral vary by bioavailability
- •Delayed gastric emptying during migraine can make non-oral routes preferable for some patients
- 1:52:12 – 2:01:35
Neuromodulation devices and cannabis: what’s available, where evidence is emerging, and practical limitations
The discussion reviews non-drug neuromodulation devices (external stimulation of trigeminal, vagal pathways, and remote electrical neuromodulation via armband). Brian then addresses cannabis use, noting high real-world use but major evidence gaps due to formulation variability and regulatory barriers.
- •Neuromodulation devices: electrical/magnetic stimulation; FDA-cleared devices for acute and/or prevention
- •Examples: supraorbital trigeminal stimulation, noninvasive vagus stimulation, armband ‘remote’ neuromodulation
- •Devices vary in cost models (purchase vs. monthly lease; per-treatment limits) and lack head-to-head comparisons
- •Cannabinoids: ~1/3 of their academic clinic population reports use; hard to interpret due to nonstandard dosing/routes
- •RCT evidence is limited and slow-moving due to regulatory constraints and feasibility challenges
- 2:01:35 – 2:09:10
When to worry: red flags for secondary headache and notes on CSF leaks
To close, Peter and Brian cover warning signs that warrant medical evaluation for secondary causes. Brian offers a practical red-flag framework (new pattern, systemic symptoms, focal neurologic signs, thunderclap onset, positional features) and highlights why CSF leaks can be missed.
- •Red flags: new onset or change in pattern, fever/rash/meningismus, unintended weight loss
- •Neurologic deficits (weakness, speech, vision, balance) require urgent evaluation
- •Age >50 with new headache raises concern (e.g., temporal arteritis)
- •Thunderclap onset and exertional/sexual/cough-provoked headaches suggest secondary etiologies
- •CSF leak clues: positional headache, ‘second-half of day’ worsening, possible interscapular pain; diagnosis/treatment can be complex
